InvestRight
Currency
Theme
$1 = ₹92.67 as of 22 Nov
DELL $278.02 -9.7% ORCL $101.19 -7.7% TTD $13.38 -7.7% AAOI $45.16 -7.4% CNL $11.70 -5.8% LRCX $210.83 -5.6% INTC $55.47 -5.4% BE $177.28 -5.4% SERV $2.50 -4.8% MU $712.42 -4.5%

Merck & Company, Inc.

MRK NYSE

There isn't enough steady cash-flow history to value Merck & Company yet. Analysts' mean target is about 13% higher.

₹13,286.10 +0.43% today as of 18 Nov, 1:15 PM
Drug Manufacturers - General
MRK snapshot, latest event consensus as of 2026-11-18

No single event this week: analyst targets span ~₹9,730–17.2K a share.

On consensus MRK is the cheapest of its peers, at ~16x next year's earnings. Otto can't build a cash-flow range for this one yet, so the range shown is the analysts' own; the price, ₹13.3K, sits inside it.

01 · Forward P/E

  • MRK ~16x
  • ABBV ~18.1x
  • GILD ~16.5x
  • JNJ ~24x

Next fiscal year's consensus earnings. P/E ÷ growth: MRK ~0.02, peers ~0.10–0.32.

02 · Latest event

No results, sharp move or standout headline in the last week.

03 · The range, a share

  • Analyst targets ~₹9,730–17.2K

Current price ₹13.3K.

~16x
Forward P/E, consensus
~0.02
P/E per point of EPS growth
₹13.3K
Price: inside the target range
~₹9,730–17.2K
Analyst target range

Forward P/E and analyst targets: Yahoo Finance consensus. No cash-flow range: the company's reported cash flows don't support one yet. Not investment advice — Otto just crunches numbers.

Price trend

+12.5% over six months · S&P 500 -8.1%

2026-05-26 · ₹11,015.24 2026-11-20 · ₹12,391.83

What think

The market's move: +12.5% over the past year

52-wk low ₹8,701.71 high ₹14,541.78

Trading 78% up its 52-week range. Price is the market's live vote — not advice.

Otto's still crunching Merck's numbers.
Select Refresh at the top of this page to pull the full statements now — it takes a few seconds.

Ownership & insiders

from SEC Form 4 filings

No insider filings saved yet — Otto checks EDGAR on each refresh.

What does this show?

Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.

Learn more on Investopedia →

Competitors

Compare Drug Manufacturers - General · tap to jump
What does this show?

A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.

Learn more on Investopedia →

In the news

My notes